Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVEO PHARMACEUTICALS, INC.AVEO · Entity 120602 | Director | February 01, 2018 | February 05, 2018 |
| Applied Therapeutics, Inc.APLT · Entity 67708 | Director · Executive Chairman | December 19, 2024 | December 21, 2024 |
| Axogen, Inc.AXGN · Entity 4297 | Director | June 24, 2026 | June 26, 2026 |
| ELI LILLY & CoLLY · Entity 2794 | Sr. VP, Oncology Business Unit | November 01, 2009 | November 10, 2009 |
| MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249 | Director · Chief Executive Officer | June 27, 2019 | July 02, 2019 |
| Ocugen, Inc.HSGX · Entity 5550 | Director | June 15, 2018 | June 19, 2018 |
| Strongbridge Biopharma plcSBBP · Entity 131608 | Director · Chief Executive Officer | October 05, 2021 | October 06, 2021 |
| Verastem, Inc.VSTM · Entity 5242 | Director | May 21, 2026 | May 26, 2026 |
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVEO PHARMACEUTICALS, INC.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.08 · Expires 2028-01-31 | Direct | 100,000 |
Reported balance
After 2018-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-01 · Grant · Acquired 100,000 · Balance 100,000 F1: This option vests in equal monthly installments from March 1, 2018 through February 1, 2021 subject to the Reporting Person's continued service to the company. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in equal monthly installments from March 1, 2018 through February 1, 2021 subject to the Reporting Person's continued service to the company.
Applied Therapeutics, Inc.
Report date December 19, 2024 · Filed December 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500,000 |
Reported balance
After 2024-12-19 transaction · row 1
1 source rowRow 1 · 2024-12-19 · Grant · Acquired 500,000 · Balance 500,000 F1: Consists of compensatory Restricted Stock Units ("RSUs") granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2034-12-19 | Direct | 1,000,000 |
Reported balance
After 2024-12-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-19 · Grant · Acquired 1,000,000 · Balance 1,000,000 F2: Consists of compensatory Options granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). The shares subject to the Option will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of compensatory Restricted Stock Units ("RSUs") granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date.
F2: Consists of compensatory Options granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). The shares subject to the Option will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date.
Axogen, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,392 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 4,392 · Balance 4,392 F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.
ELI LILLY & Co
Report date November 01, 2009 · Filed November 10, 2009
This filing explicitly reported no securities owned.
MELINTA THERAPEUTICS, INC. /NEW/
Report date June 27, 2019 · Filed July 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Melinta Common StockSEC Table I · non-derivative | Direct | 37,400 |
Reported balance
After 2019-06-27 transaction · row 1
1 source rowRow 1 · 2019-06-27 · Sale · Disposed 13,000 · Balance 37,400 F1: Represents the number of shares necessary to cover tax withholding obligations in connection with the vesting of the Reporting Person's RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares necessary to cover tax withholding obligations in connection with the vesting of the Reporting Person's RSUs.
Ocugen, Inc.
Report date June 15, 2018 · Filed June 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2028-06-14 | Direct | 25,000 |
Reported balance
After 2018-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-15 · Grant · Acquired 25,000 · Balance 25,000 F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.
Strongbridge Biopharma plc
Report date October 05, 2021 · Filed October 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 1
1 source rowRow 1 · 2021-10-05 · Disposition to issuer · Disposed 610,092 · Balance 0 F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-10-05 · Disposition to issuer · Disposed 495,724 · Balance 0 F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.
F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.
Verastem, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,666 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 36,000 · Balance 52,666 F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
Xeris Biopharma Holdings, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 707,276 |
Ending reported balance
After 2026-06-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-04 · Sale · Disposed 15,000 · Balance 683,083 F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 2 · 2026-06-04 · Grant · Acquired 24,193 · Balance 707,276 F3: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2036-06-04 | Direct | 32,996 |
Reported balance
After 2026-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-04 · Grant · Acquired 32,996 · Balance 32,996 F4: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
F4: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PORTOLA PHARMACEUTICALS INC
Report date July 02, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 1
1 source rowRow 1 · 2020-07-02 · Disposition to issuer · Disposed 13,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 2
1 source rowRow 2 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-02 · Disposition to issuer · Disposed 54,991 · Balance 0 F4: In connection with the Merger, these options were accelerated and canceled without payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
F4: In connection with the Merger, these options were accelerated and canceled without payment.
Sucampo Pharmaceuticals, Inc.
Report date February 13, 2018 · Filed February 13, 2018
Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Class ASEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 1
1 source rowRow 1 · 2018-02-13 · Disposition to issuer · Disposed 5,130 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.92 · Expires 2024-12-10 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.23 · Expires 2025-05-29 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-13 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2025-05-29 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-13 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.
F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2018 Filed Jun 14, 2018 16:58 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantStock Option (right to buy) · Derivative | 9,100 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0000899243-18-016640 · doc4.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 16:58 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0000899243-18-016640 · doc4.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. F2 · derivative.exercise_date: One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 22:14 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $42.81 | $0.00 |
DisclosureSEC source: 0001209191-18-036765 · doc4.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-07 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 22:14 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036765 · doc4.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| May 15, 2018 Filed May 17, 2018 12:40 UTC | Strongbridge Biopharma plc SBBP · Entity 131608 | GrantStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0001179110-18-006948 · edgar.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-05-15 Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 21:52 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 10,000 | $7.70 Strike: $10.30 | $77,000.00 |
DisclosureSEC source: 0001171843-18-001105 · form4.xml · derivative · entry 4 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-05-29 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 21:52 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 20,000 | $1.77 Strike: $16.23 | $35,400.00 |
DisclosureSEC source: 0001171843-18-001105 · form4.xml · derivative · entry 3 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-05-29 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 21:52 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 30,000 | $4.08 Strike: $13.92 | $122,400.00 |
DisclosureSEC source: 0001171843-18-001105 · form4.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2024-12-10 F2 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 21:52 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerCommon Stock, Class A | 5,130 | $18.00 | $92,340.00 |
DisclosureSEC source: 0001171843-18-001105 · form4.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:30 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000899243-18-002926 · doc4.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: This option vests in equal monthly installments from March 1, 2018 through February 1, 2021 subject to the Reporting Person's continued service to the company. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 22:07 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $35.06 | $0.00 |
DisclosureSEC source: 0001209191-17-040919 · doc4.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-16 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest each month after June 1, 2017, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 22:07 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040919 · doc4.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2018, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 21:01 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000899243-17-016393 · doc4.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 13, 2017. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 01:55 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.30 | $0.00 |
DisclosureSEC source: 0001171843-17-003479 · f4_johnson060517.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Class A Common Stock · 10,000 shares Expires 2027-06-01 F2 · derivative.exercise_date: Vesting commences July 1, 2017 in 12-monthly installments. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 01:55 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-003479 · f4_johnson060517.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,930 F1 · security: Common stock granted consists of restricted stock units that vest in a single installment on June 1, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:54 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002486 · doc4.xml · derivative · entry 9 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-02 F8 · derivative.exercise_date: The option vests on the following schedule: 1/12th of the shares vest monthly at the end of each month over 12 months, beginning after 01/01/2017. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 22:05 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0000899243-16-035946 · doc4.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-12-16 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 22, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.